Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Champions Oncology (NASDAQ:CSBR) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(...
Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stoc...
Champions Oncology (NASDAQ:CSBR) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(...
Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive ma...
Craig-Hallum analyst Matt Hewitt maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $8 t...
